Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

N Engl J Med. 2023 Jun 15;388(24):2299. doi: 10.1056/NEJMc2304782.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Dermatitis, Atopic* / drug therapy
  • Humans

Substances

  • lebrikizumab
  • Antibodies, Monoclonal